HOME >> BIOLOGY >> NEWS
REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement

, data was analyzed from the REMICADE 5 mg/kg every eight week maintenance arm of each trial, the only regimen common to both EXPRESS and EXPRESS II. At week 10, after infusions at weeks 0, 2, and 6, the proportions of patients achieving PASI 75 were 80 percent versus three percent of placebo patients for EXPRESS and 75 percent versus two percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). At week 10, the proportions of patients achieving PASI 90, or nearly complete skin clearance, were 57 percent versus one percent of placebo patients for EXPRESS and 45 percent versus 0.5 percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). PASI 75 responses achieved at week 10 were maintained through week 26 in both EXPRESS and EXPRESS II (81 percent and 78 percent of patients achieved at least PASI 75 improvement from baseline, respectively), and the majority of patients achieved PASI 75 at week 50 in the REMICADE 5 mg/kg every eight-week maintenance groups.

"These data show great potential for REMICADE in the treatment of a disease that often carries great physical and emotional challenges," said Robert Matheson, MD, Oregon Medical Research Center, and study investigator. "The potential of achieving nearly complete skin clearance is exciting and holds great promise for patients with this difficult to treat disease."

Investigators reported that at week 10 patients in both EXPRESS and EXPRESS II receiving REMICADE experienced improvements in the Dermatology Life Quality Index (DLQI) and Physician's Global Assessment (PGA), measures of quality of life and psoriasis severity, respectively. In both studies, following 5 mg/kg induction therapy, REMICADE-treated patients experienced a median improvement of nine points in DLQI, a change that is considered to be a clinically meaningful decrease in psoriasis-related burden for the patient, compared to no improvement for placebo patients (REMICADE vs. placebo, -9.0 ve
'"/>

Contact: Michael Parks
215-983-8000
Centocor, Inc.
3-Mar-2006


Page: 1 2 3

Related biology news :

1. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients
2. Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis
3. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
4. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
5. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
8. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
9. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
10. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
11. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... ... 2017 , ... As part of the Stago EdVantage Virtual University ... DIC in order to illuminate this clinical problem for people unfamiliar with the topic. ... in a high degree of morbidity and mortality. DIC is a confusing disorder from ...
(Date:4/25/2017)... Providence -based biotechnology ... technology to an undisclosed global pharmaceutical company, for ... Tregitopes, pronounced T·rej·itopes, are a set of peptides ... Annie De Groot and EpiVax CIO ... autoimmune disease therapy, Tregitopes are capable of engaging regulatory ...
(Date:4/25/2017)... ... ... Leaders of Quorum Review IRB and Kinetiq , the ... week’s Association of Clinical Research Professionals (ACRP) 2017 Meeting & Expo with ... are excited to present subject matter expertise on topics that impact the global clinical ...
(Date:4/21/2017)... COLORADO (PRWEB) , ... April 21, 2017 , ... ... Awards recognized outstanding manufactures in 10 categories with over 30 nominees and well ... in Manufacturing presented the new award and the event was hosted by CompanyWeek ...
Breaking Biology Technology:
Cached News: